Hepatitis C virus nonstructural antigen-derived peptide–Major histocompatibility complex complex (HCV NS antigen–MHC complex)

Hepatitis C virus nonstructural (NS) antigen-derived peptides presented on major histocompatibility complex (MHC) molecules describes a key immunological process in which peptides generated from HCV nonstructural proteins (including NS3, NS5A, and others) are processed in the infected cell and loaded onto MHC molecules (class I or II) for display on the cell surface. This presentation is crucial for immune recognition; CD8+ T cells recognize peptides presented on MHC class I, while CD4+ T cells recognize those on MHC class II. The efficiency and specificity of peptide–MHC presentation dictate the outcome of infection, influencing viral clearance, chronicity, and immune escape. HCV can evade this process via mutations in epitopes or modulation of antigen presentation pathways, thus impairing T-cell recognition and contributing to persistence of infection. The MHC–peptide complex itself is not a conventional drug target, but the antigens and MHC-restricted immune responses are central to vaccine and immunotherapeutic strategies targeting hepatitis C. Note: The entry does not correspond to a singular protein, receptor, or pharmacological target as usually defined, but rather to a specific immune recognition event between viral peptides (from HCV nonstructural proteins) and host MHC molecules important for antiviral immunity and thus relevant for immunotherapy development.

Other names

HCV NS3/NS5–MHC complexHepatitis C virus nonstructural peptide–MHC complexHCV antigen–MHC complex

DAAs: Inhibit HCV replication, lowering antigen load, indirectly modulating the availability of viral peptides presented by MHC. Peptide vaccines: Enhance T-cell recognition by increasing the frequency of HCV-specific, MHC-restricted T cells. Immunotherapeutics: Some approaches aim to boost T-cell responses specific for viral peptide–MHC complexes.